Another intriguing facet of the TGF-β1 switch is evident in breast cancer, where the TGF-β1-induced transmembrane prostate androgen-induced protein (TMEPAI), which is highly expressed in various types of cancers, has been proposed to act as a TGF-β oncogenic switch [301]. This evidence concerns the gene PMEPA1 and breast cancer.